MedPath

Fluzoparib

Generic Name
Fluzoparib
Drug Type
Small Molecule
Chemical Formula
C22H16F4N6O2
CAS Number
1358715-18-0
Unique Ingredient Identifier
TWF0ML1CK8
Background

Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).

Indication

⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。

Clinical Trials
Related News

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

Phase 2
Recruiting
Conditions
Her-2 Negative Breast Cancer
HRR Gene Mutation
Interventions
First Posted Date
2023-03-09
Last Posted Date
2023-03-09
Lead Sponsor
Ying Lin
Target Recruit Count
66
Registration Number
NCT05761470
Locations
🇨🇳

First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Phase 2
Recruiting
Conditions
Breast Cancer Metastatic
Interventions
Drug: Fulvestrant/AI
First Posted Date
2023-03-08
Last Posted Date
2024-02-06
Lead Sponsor
Fudan University
Target Recruit Count
200
Registration Number
NCT05759546
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Phase 2
Recruiting
Conditions
Ovarian Neoplasms
Ovarian Diseases
Interventions
First Posted Date
2023-03-03
Last Posted Date
2024-02-06
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
37
Registration Number
NCT05753826
Locations
🇨🇳

Fujian Cancer Hospital, Fujian, China

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Phase 2
Not yet recruiting
Conditions
Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
Interventions
First Posted Date
2023-02-16
Last Posted Date
2023-02-24
Lead Sponsor
Fudan University
Target Recruit Count
29
Registration Number
NCT05732129
Locations
🇨🇳

Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Phase 2
Recruiting
Conditions
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
Interventions
Drug: Fluzoparib+Camrelizumab
First Posted Date
2022-12-19
Last Posted Date
2023-01-31
Lead Sponsor
wang shusen
Target Recruit Count
80
Registration Number
NCT05656131
Locations
🇨🇳

Sun-yat sen university cancer center, Guangzhou, Guangdong, China

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2
Recruiting
Conditions
HER2-negative Breast Cancer
Advanced Breast Cancer
Breast Neoplasm
Breast Cancer
Hormone Receptor Positive Tumor
Interventions
Drug: AKT inhibitor
Drug: Carrelizumab
Drug: SHR-1167
Drug: TPC
Drug: SHR-6209
First Posted Date
2022-10-26
Last Posted Date
2024-10-04
Lead Sponsor
Fudan University
Target Recruit Count
620
Registration Number
NCT05594095
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 2
Recruiting
Conditions
Ovarian Cancer
Interventions
Biological: QL1101
First Posted Date
2022-10-18
Last Posted Date
2023-07-28
Lead Sponsor
Yongpeng Wang
Target Recruit Count
25
Registration Number
NCT05585281
Locations
🇨🇳

Yongpeng Wang, Shenyang, China

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase 2
Recruiting
Conditions
Breast Neoplasm
HER2-positive Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Breast Cancer
Breast Tumors
Hormone Receptor Negative Tumor
Triple-Negative Breast Cancer (TNBC)
Locally Advanced Breast Cancer
Early-stage Breast Cancer
Interventions
First Posted Date
2022-10-17
Last Posted Date
2024-12-27
Lead Sponsor
Fudan University
Target Recruit Count
716
Registration Number
NCT05582499
Locations
🇨🇳

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Phase 2
Not yet recruiting
Conditions
Relapsed Ovarian Cancer
Interventions
Drug: Fluzoparib+Apatinib
First Posted Date
2022-07-29
Last Posted Date
2022-07-29
Lead Sponsor
Xiaohua Wu MD
Target Recruit Count
132
Registration Number
NCT05479487

A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects

Phase 1
Completed
Conditions
Solid Tumor
Interventions
First Posted Date
2022-06-30
Last Posted Date
2022-09-08
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
20
Registration Number
NCT05440006
Locations
🇨🇳

Wannan Medical College Yijishan Hospital, Wuhu, Anhui, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy